ACTRN12613001286730已完成1 期
A single-dose, single-blinded, balanced, randomised, three-treatment, three-period, three-sequence bioequivalence study of 5 mg oxycodone tablets in a 3 way crossover comparison against the innovator 5 mg oxycodone tablet under fasting conditions in both male and female volunteers.
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 24
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomised controlled trial
- 主要目的
- Treatment
- 盲法
- Blinded (masking used)
入排标准
- 年龄范围
- 18 Years 至 55 Years（—）
- 性别
- All
入选标准
- •Healthy males and non-pregnant females
- •Aged between 18 and 55
- •Non-smoker
- •BMI between 19 and 30
- •Normal, healthy individuals as determined by medical history, physical examination, ECG, bood pressure and laboratory tests
- •Able to provide written informed consent
排除标准
- •Any history of recent recurrent attacks of bronchitis, asthma, migraine headaches
- •Concomitant drug therapy of any kind excluding prescribed hormonal contraceptives
- •Who have receievd an investigational compound or drug known to induce or inhibit liver enzymes within 60 days of the start of the study
- •History or family history of depression or other mental illness, epilepsy or seizures
- •Sensitivity to oxycodone, any opioid analgesic medicines, excipients of oxycodone
- •History of any conditions that might interfere with the absorption, distribution, metabolism or excretion of the drug
- •Who are lactose intolerant
- •Females who are breastfeeding or are planning to start a family within 60 days of dosing
- •Who are planning on having any surgical or dental procedures within 4 weeks of the study completion
- •Smoker (anyone who has smoked in the last 6 months)
- •History of alcohol or drug abuse or dependency
- •Participation in a drug study within 60 days of the start of the study or donated blood in the 60 days preceding the study.
- •Volunteers for whom the Clinical Investigator believes, for any reason, that participation would not be an acceptable risk.
研究者
相似试验
已完成
1 期
Comparative assessment of the absorption of two generic formulations of doxycycline delayed release capsule against the innovator doxycycline delayed release tablet conducted under fasting conditions in healthy male and female volunteersPilot bioequivalence study conducted in healthy volunteers comparing three formulations of doxycycline with no health condition or problem studied. Although this study is being conducted in healthy volunteers who are not being treated for the condition to which the medicine is used, doxycycline belongs to a class of medicines called a tetracyclines that are used to treat a wide range of organisms and work by killing or stopping the growth of bacteria, which cause infections or make acne worse.Pilot bioequivalence study conducted in healthy volunteers comparing three formulations of doxycycline with no health condition or problem studied.Although this study is being conducted in healthy volunteers who are not being treated for the condition to which the medicine is used, doxycycline belongs to a class of medicines called a tetracyclines that are used to treat a wide range of organisms and work by killing or stopping the growth of bacteria, which cause infections or make acne worse.Other - Research that is not of generic health relevance and not applicable to specific health categories listed aboveACTRN12614000267651Zenith Technology Corp Ltd12
已完成
1 期
Comparative assessment of the absorption of a generic formulation of paracetamol / ibuprofen / doxylamine tablet against the innovator paracetamol / codeine phosphate hemihydrate / doxylamine succinate tablets and paracetamol / ibuprofen tablet conducted under fasting conditions in healthy male and female volunteersPainFeverInflammationInflammatory and Immune System - Other inflammatory or immune system disordersAnaesthesiology - Pain managementAllergyACTRN12619001017112Zenith Technology Corporation Limited24
撤回
1 期
Comparative assessment of the absorption of a generic formulation of 4,5-epoxy-3-methoxy-17-methylmorphinan-6-ol hydrogen tartrate oral liquid against the innovator 4,5-epoxy-3-methoxy-17-methylmorphinan-6-ol hydrogen tartrate oral liquid conducted under fasting conditions in healthy male and female volunteers.4,5-epoxy-3-methoxy-17-methylmorphinan-6-ol hydrogen tartrate oral liquid is used to provide temporary relief for persistent unproductive and dry coughsAnaesthesiology - Pain managementInflammatory and Immune System - Other inflammatory or immune system disordersRespiratory - Other respiratory disorders / diseasesACTRN12621001252808Zenith Technology Corporation Limited30
已完成
不适用
To check the difference of two products that is product A (Xtenergy caffeine 60%, 200 mg caffeine/ Capsule) and product B (Natural caffeine extract 99%,200 mg caffeine/Capsule) in the healthy adult human beings.CTRI/2019/11/022135OmniActive Health Technologies Ltd26
进行中（未招募）
不适用
A single dose, randomized, double blind, double dummy, placebo controlled, three-period crossover clinical study, comparing the onset of relief from methacholine induced bronchoconstriction with fixed combination beclomethasone dipropionate 100 µg plus formoterol fumarate 6 µg/actuation pMDI with HFA-134a propellant (Foster) versus standard salbutamol pMDI 100 µg/actuation (Ventolin Evohaler) therapy in asthmatic patients. - MART 1 Maintenance And Reliever TherapyAshtmaMedDRA version: 9.1Level: LLTClassification code 10003553Term: AsthmaEUCTR2008-000905-12-ITCHIESI